Shanghai Medicilon Inc.

  On April 4, 2024, A Cancer Journal for Clinicians (CA), the top journal with the No. 1 impact factor, released the report "Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Rates of 36 Cancer in 185 Countries".  The report points out that there will be nearly 20 million new cancer cases worldwide in 2022, and the number of cancer deaths will be 9.7 million.  These data indicate that approximately one in five men or women will develop cancer in their lifetime, and one in 9 men and one in 12 women may die from cancer.  Predictions show that by 2050, new cancer cases worldwide may climb to 35 million, highlighting the severe challenges facing cancer treatment. April 17 is World Cancer Day and April 15-21 is National Cancer Prevention and Treatment Awareness Week.  These special days aim to draw global public attention to cancer, a serious public health issue, and to promote progress in cancer prevention and treatment.  The just-con...

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

  1 E3 Ligase-CRBN、E3 Ligase-VHL、PROTAC linker…… Common building blocks in literature, In reality, it's hard to find one! Are you also searching for this? PROTAC Building Blocks Pharmlego TM  has developed more than 600 types of Linker and E3 ligase ligand building blocks, covering common long carbon chains, ethylene glycol long chains, spiroheterocyclic chains, CRBN, VHL, cIAP and MDM2 ligands and other chemical structures. ○E3 Ligase-CRBN＞100 ○E3 Ligase-VHL＞100 ○E3 Ligase-others ＞50 ○PROTAC linker＞1000 *If we cannot meet your needs, we can also customize it for you. For more: https://cn.pharmalego.com/service/protac-custom.html 2  Sugar unit intermediates, base intermediates, delivery systems... It is an intermediate that is obviously not difficult to synthesize. But, it just takes a lot of time to synthesize! Are you also doing this for 996 and 007? Nucleic Acid Drugs Pharmalego TM  can efficiently and quickly provide customization and research and development ser...

  On September 27, the "STAR Summit" was grandly held in Shanghai.  The Summit announced the selection list for the fourth anniversary of science and technology innovation. Shanghai Medicilon Inc (Medicilon) has been selected as a " 2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise" based on its hard-core advantages in biopharmaceutical technology innovation over the years. Technological innovation is the key to winning the future, and it is also what Medicilon is committed to pursuing.  Over the past 19 years, Medicilon has continued to increase investment in research and development, focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA vaccines , PROTAC , ADC , bi/multi-specific antibodies and established an innovative service platform to help promote the "hard core" of drugs.  In order to deepen the collaboration between the industry, academia and research institutions, Medicilon also...

  To date, there are few literature reports that summarize PROTAC metabolism studies. Therefore, in this article, we share some examples of DMPK studies of   PROTAC   with the experience of the Medicilon   DMPK   department and hope to be helpful to all researchers who are interested in PROTAC molecular DMPK. Prostate cancer is a common malignancy in men, and the development of effective therapies for prostate cancer has been a primary focus of scientific research. The prostate is an androgen-dependent organ, and prostate cancer is an androgen-dependent disease. Androgen action is mediated by the androgen receptor (AR), a hormone-activated transcription factor that belongs to the nuclear receptor superfamily of steroid receptors. AR and its downstream signaling play a vital role in the development and progression of localized and metastatic prostate cancer. Androgen receptor (AR) structure  [1] The primary treatment for metastatic prostate cancer is androge...